Anamar AB is a pharmaceutical company based in Lund, specializing in the development of novel medicines aimed at treating fibrosis. The company focuses on AM1476, which is identified as a selective 5-HT 2B receptor antagonist. This compound has shown dual-action potential, targeting skin and lung issues that are associated with systemic sclerosis, a condition characterized by the hardening and tightening of the skin and connective tissues.
The company has progressed its research to Phase II clinical trials, following successful outcomes in Phase I and preclinical studies. Anamar AB is committed to advancing innovative solutions within the field of fibrosis treatment, placing a strong emphasis on research and development to address unmet medical needs. Through its efforts, the company aims to contribute significantly to the understanding and management of fibrotic diseases.